Mymetics Corp.
Mymetics Corp. is a privately held Swiss biotechnology company founded in 1990, headquartered in Epalinges, Switzerland, with 1-10 employees and led by CEO and owner Grant E. Pickering. Its specific product pipeline, technology platform, customers, and current operating status are not publicly disclosed, with its corporate website currently in maintenance mode.
- Company typePrivate
- Founded1990
- HeadquartersEpalinges, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingServices
Mymetics Corp. firmographics
Firmographics- Name
- Mymetics Corp.
- Legal name
- Mymetics Corp.
- Website
- https://mymetics.com
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Mymetics Corp. is a privately held Swiss biotechnology company founded in 1990, headquartered in Epalinges, Switzerland, with 1-10 employees and led by CEO and owner Grant E. Pickering. Its specific product pipeline, technology platform, customers, and current operating status are not publicly disclosed, with its corporate website currently in maintenance mode.
- Ownership category
- akta.pro rank
Where Mymetics Corp. is headquartered
LocationHeadquarters
- HQ city
- Epalinges
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Mymetics Corp. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Mymetics Corp. product offering
Product offeringCore offering
Mymetics Corp. is described as a Swiss-based biotechnology company. No specific products, services, or pipeline details are available in the provided sources because the company website is in maintenance mode.
Differentiator
Problem solved
Functional benefit
Companies that use Mymetics Corp.
Customer profileIdeal customer profiles1 record
Mymetics Corp. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Mymetics Corp. competitors and assessment
Company assessmentDirect peers
- Novavax: Clinical-stage vaccine developer using recombinant nanoparticle technology, comparable to Mymetics as a non-mRNA vaccine platform company with a similarly constrained commercialization track record.
- Hookipa Pharma: Austrian clinical-stage biotech developing vaccines using viral vector platforms (arenavirus-based), directly comparable to Mymetics' historical virosome vaccine approach as a small European vaccine platform company.
- OSIVAX: French biotech developing broad-spectrum vaccines using its oligoDOM virosome-like technology platform — the most direct technical analog to Mymetics' virosome vaccine heritage.
- VBI Vaccines: Clinical-stage biopharmaceutical company developing vaccines using enveloped virus-like particle (eVLP) technology, comparable to Mymetics as a small-cap virosome-adjacent vaccine platform.
- CureVac: German-headquartered clinical-stage vaccine developer comparable in European domicile and pre-commercial biotech profile, though pursuing an mRNA platform rather than virosome.
- Valneva: European specialty vaccine company focused on travel and infectious disease vaccines, comparable as a European-domiciled specialty vaccine developer of similar vintage to Mymetics.
- Bavarian Nordic: Danish vaccine company developing smallpox, RSV, and other infectious disease vaccines — comparable as a European-headquartered specialty vaccine developer operating in infectious disease.
- GeoVax Labs: US clinical-stage biotech developing vaccines using its Modified Vaccinia Ankara (MVA) platform — a small-cap vaccine platform company comparable in scale and stage to Mymetics.
Broad incumbents
- BioNTech: German mRNA vaccine giant; serves as a broad incumbent benchmark that has eclipsed legacy virosome approaches with mRNA technology, defining the competitive context Mymetics historically operated in.
- Moderna: US-based mRNA vaccine leader; functions as a broad incumbent that has reshaped the vaccine platform space where Mymetics historically competed, providing a scale and capital benchmark.
Market position
Customer concentration
Mymetics Corp. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mymetics Corp. leadership team
Management profileNumber of profiles
Profiles1 record
Mymetics Corp. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mymetics Corp. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mymetics Corp.
What does Mymetics Corp. do?
Mymetics Corp. is described as a Swiss-based biotechnology company. No specific products, services, or pipeline details are available in the provided sources because the company website is in maintenance mode.
When was Mymetics Corp. founded?
Mymetics Corp. was founded in 1990. It employs 1 to 10 people.
Where is Mymetics Corp. based?
Mymetics Corp. is headquartered in Epalinges, Switzerland, in the Europe region.
Who are Mymetics Corp.'s main competitors?
Direct peers on record are Novavax, Hookipa Pharma, OSIVAX, VBI Vaccines, CureVac, Valneva, Bavarian Nordic and GeoVax Labs. Broad incumbents are BioNTech and Moderna.
Does Mymetics Corp. have an API?
No public API is recorded for Mymetics Corp..